J&J’s Janssen Pharmaceutical will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority.
- The collaborative partnership with BARDA builds on Johnson & Johnson’s multipronged response to the new coronavirus disease outbreak.
- Janssen and BARDA will both contribute to R&D costs and mobilize resources to rapidly advance the initial stages of Janssen’s COVID-19 vaccine development program
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story: